Skip to main content
SpringerLink
Log in

Pharmacological Management of Pediatric Patients with Comorbid Attention-Deficit Hyperactivity Disorder Oppositional Defiant Disorder

  • Therapy in Practice
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a common developmental neurobiological condition of childhood characterized by age-inappropriate degrees of hyperactivity/impulsivity and inattention to tasks requiring sustained vigilance. Oppositional defiant disorder (ODD) is an externalizing behavior disorder characterized by difficulties with emotional and behavioral regulation that frequently brings the child into conflict with authority figures. In the clinical setting, ODD is the most common ADHD comorbidity. The combination portends more severe symptom severity, daily impairment, and a more at-risk prognosis than either disorder alone. We briefly review the literature on the characteristics and treatment of the ADHD and ODD child. A clinical approach to evaluation and treatment of ADHD and ODD is then presented. This approach emphasizes the importance of child and parent psychoeducation about the two disorders alone and in combination, the importance of behavioral management therapy approaches, the possible need for school and academic supports, and the decision to use evidence-based stimulant or non-stimulant ADHD medications depending on symptom severity combined with child and parental wishes and choice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Publishing; 2013.

    Google Scholar 

  2. World Health Organization. International classification of diseases and related health problems. Geneva, Switzerland: WHO; 1992.

    Google Scholar 

  3. Multimodal Treatment of ADHD Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56(12):1073–86.

    Article  Google Scholar 

  4. Pliszka SR. Comorbid psychiatric disorder in children with ADHD. In: Barkley RA, editor. Attention-deficit hyperactivity disorder: a handbook for diagnosis & treatment. 4th ed. New York: Guilford Press; 2015. p. 140–68.

    Google Scholar 

  5. Swanson J, Arnold LE, Kraemer H, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord. 2008;12(1):4–14.

    Article  PubMed  Google Scholar 

  6. Barkley RA, Murphy KR, Fischer M. ADHD in adults. What the science says. New York: Guilford Press; 2008.

    Google Scholar 

  7. Connor DF, Doerfler LA. ADHD with comorbid oppositional defiant disorder or conduct disorder: discrete or nondistinct disruptive behavior disorders? J Atten Disord. 2008;12(2):126–34.

    Article  PubMed  Google Scholar 

  8. Connor DF, Steeber J, McBurnett K. A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder. J Dev Behav Pediatr. 2010;31(5):427–40.

    Article  PubMed  Google Scholar 

  9. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006;45(2):192–202.

    Article  PubMed  Google Scholar 

  10. Beauchaine TP, Hinshaw SP, Pang KL. Comrobidity of attention-deficit/hyperactivity disorder and early-onset conduct disorder: Biological, environmental, and developmental mechanisms. Clin Psychol: Sci Pract. 2010;17:327–36.

    Google Scholar 

  11. Waldman ID, Lahey BB. Oppositional defiant disorder, conduct disorder, and juvenile delinquency. In: Beauchaine TP, Hinshaw SP, editors. Child and adolescent psychopathology. 2nd ed. Hoboken, New Jersey: Wiley; 2013. p. 411–52.

    Google Scholar 

  12. Taylor E, Chadwick O, Heptinstall E, et al. Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry. 1996;35(9):1213–26.

    Article  CAS  PubMed  Google Scholar 

  13. De Pauw SS, Mervielde I. Temperament, personality and developmental psychopathology: a review based on the conceptual dimensions underlying childhood traits. Child Psychiatry Hum Dev. 2010;41(3):313–29.

    Article  PubMed  Google Scholar 

  14. Dishion TJ, Racer KH. Development of adult antisocial behavior. In: Beauchaine TP, Hinshaw SP, editors. Child and adolescent psychopathology. 2nd ed. Hoboken, New Jersey: Wiley; 2013. p. 453–87.

    Google Scholar 

  15. Steiner H, Remsing L. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):126–41.

    Article  PubMed  Google Scholar 

  16. Lahey BB, Waldman ID, McBurnett K. Annotation: the development of antisocial behavior: an integrative causal model. J Child Psychol Psychiatry. 1999;40(5):669–82.

    Article  CAS  PubMed  Google Scholar 

  17. Pfiffner LJ, McBurnett K, Rathouz PJ, et al. Family correlates of oppositional and conduct disorders in children with attention deficit/hyperactivity disorder. J Abnorm Child Psychol. 2005;33(5):551–63.

    Article  PubMed  Google Scholar 

  18. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr. 2001;22(1):60–73.

    Article  CAS  PubMed  Google Scholar 

  19. Burke JD, Loeber R, Lahey BB, et al. Developmental transitions among affective and behavioral disorders in adolescent boys. J Child Psychol Psychiatry. 2005;46(11):1200–10.

    Article  PubMed  Google Scholar 

  20. Loeber R, Green SM, Lahey BB, et al. Findings on disruptive behavior disorders from the first decade of the Developmental Trends Study. Clin Child Fam Psychol Rev. 2000;3(1):37–60.

    Article  CAS  PubMed  Google Scholar 

  21. Villodas MT, Pfiffner LJ, McBurnett K. Prevention of serious conduct problems in youth with attention deficit/hyperactivity disorder. Expert Rev Neurother. 2012;12(10):1253–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Satterfield JH, Faller KJ, Crinella FM, et al. A 30-year prospective follow-up study of hyperactive boys with conduct problems: adult criminality. J Am Acad Child Adolesc Psychiatry. 2007;46(5):601–10.

    Article  PubMed  Google Scholar 

  23. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36:85S–121S.

    Article  Google Scholar 

  24. American Academy of Child and Adolescent Psychiatry. Practice parameters for the psychiatric assessment of children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;31(10 Suppl):1386–402.

    Google Scholar 

  25. Achenbach TM, Ruffle TM. The Child Behavior Checklist and related forms for assessing behavioral/emotional problems and competencies. Pediatr Rev. 2000;21(8):265–71.

    Article  CAS  PubMed  Google Scholar 

  26. Conners CK. Conners Rating Scales-Revised, 3rd edn. North Tonawanda, NY: Multi-Health Systems; 2008.

    Google Scholar 

  27. Reynolds C, Kamphaus R. Behavioral assessment system for children. Circle Pines, MN: American Guidance Service; 2004.

    Google Scholar 

  28. Swanson JM. The SNAP-IV Teacher and Parent Rating Scale. http://www.adhd.net/snap-iv-form.pdf. Accessed 25 Nov 2014.

  29. Vanderbilt ADHD Diagnostic Parent Rating Scale (VADPRS). http://imaging.cmpmedica.com/CME/pt/PDF/VADPRS_Quest.pdf. Accessed 25 Nov 2014.

  30. Barkley RA. Attention-deficit hyperactivity disorder. A handbook for diagnosis & treatment. 4th ed. New York: Guilford Press; 2015.

    Google Scholar 

  31. Sonuga-Barke EJ. Causal models of attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry. 2005;57(11):1231–8.

    Article  PubMed  Google Scholar 

  32. Nigg JT, Willcutt EG, Doyle AE, et al. Causal heterogeneity in attention-deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry. 2005;57(11):1224–30.

    Article  PubMed  Google Scholar 

  33. Pfiffner LJ, Haack LM. Behavior management for school-aged children with ADHD. Child Adolesc Psychiatr Clin N Am. 2014;23(4):731–46.

    Article  PubMed  Google Scholar 

  34. Evans SW, Schultz BK, Sadler JM. Safety and efficacy of psychosocial interventions used to treat children with attention-deficit/hyperactivity disorder. Pediatr Ann. 2008;37(1):52–9.

    Article  PubMed  Google Scholar 

  35. Comer JS, Chow C, Chan PT, et al. Psychosocial treatment efficacy for disruptive behavior problems in very young children: a meta-analytic examination. J Am Acad Child Adolesc Psychiatry. 2013;52(1):26–36.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Faraone SV, Antshel KM. Towards an evidence-based taxonomy of nonpharmacologic treatments for ADHD. Child Adolesc Psychiatr Clin N Am. 2014;23(4):965–72.

    Article  PubMed  Google Scholar 

  37. Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther. 2006;28(3):402–18.

    Article  CAS  PubMed  Google Scholar 

  38. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24(9):755–68.

    CAS  PubMed  Google Scholar 

  39. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2001;40(8):922–8.

    Article  CAS  PubMed  Google Scholar 

  40. Multimodal Treatment of ADHD Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56(12):1088–96.

    Article  Google Scholar 

  41. Multimodal Treatment of ADHD Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113(4):754–61.

    Article  Google Scholar 

  42. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19(4):353–64.

    Article  PubMed  Google Scholar 

  43. Cheng JYW, Chen RYL, Ko JSN, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-review. Psychopharmacology. 2007;194:197–209.

    Article  CAS  PubMed  Google Scholar 

  44. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled. Dose Response Study. Pediatrics. 2001;108(5):1–9.

    Article  Google Scholar 

  45. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73–84.

    Article  PubMed  Google Scholar 

  46. Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. J Child Adolesc Psychopharmacol. 2013;23(5):308–19.

    Article  CAS  PubMed  Google Scholar 

  47. Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155–65.

    Article  PubMed  Google Scholar 

  48. Blader JC, Pliszka SR, Jensen PS, et al. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. Pediatrics. 2010;126(4):e796–806.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Schachar RJ, Tannock R, Cunningham CE, et al. Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am Acad Child Adolesc Psychiatry. 1997;36(6):754–63.

    Article  CAS  PubMed  Google Scholar 

  50. Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics. 2008;121(2):e314–20.

    Article  PubMed  Google Scholar 

  51. Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry. 2005;44(3):240–8.

    Article  PubMed  Google Scholar 

  52. Palumbo DR, Sallee FR, Pelham WE Jr, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180–8.

    Article  PubMed  Google Scholar 

  53. Findling RL, McBurnett K, White C, et al. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(5):245–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Gadow KD, Nolan EE, Sverd J, et al. Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. J Child Neurol. 2008;23(9):981–90.

    Article  PubMed  Google Scholar 

  55. Aman MG, Bukstein OG, Gadow KD, et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014;53(1):47 e1–60 e1.

    Article  Google Scholar 

  56. DuPaul GJ, Gormley MJ, Laracy SD. School-based interventions for elementary school students with ADHD. Child Adolesc Psychiatr Clin N Am. 2014;23(4):687–97.

    Article  PubMed  Google Scholar 

  57. Robin AL. Family therapy for adolescents with ADHD. Child Adolesc Psychiatr Clin N Am. 2014;23(4):747–56.

    Article  PubMed  Google Scholar 

  58. Mikami AY, Jia M, Na JJ. Social skills training. Child Adolesc Psychiatr Clin N Am. 2014;23(4):775–88.

    Article  PubMed  Google Scholar 

  59. Antshel KM, Olszewski AK. Cognitive behavioral therapy for adolescents with ADHD. Child Adolesc Psychiatr Clin N Am. 2014;23(4):825–42.

    Article  PubMed  Google Scholar 

  60. Antshel KM. Psychosocial interventions in attention-deficit/hyperactivity disorder: update. Child Adolesc Psychiatr Clin N Am. 2015;24(1):79–97.

    Article  PubMed  Google Scholar 

  61. Connor DF. Stimulant and nonstimulant medications for childhood ADHD. In: Barkley RA, editor. Attention-Deficit hyperactivity disorder: a handbook for diagnosis & treatment. 4th ed. New York: Guilford Press; 2015. p. 666–85.

    Google Scholar 

  62. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):1033–44.

    Article  Google Scholar 

  63. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression. I: a meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry. 2002;41(3):253–61.

    Article  PubMed  Google Scholar 

  64. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.

    Article  PubMed  Google Scholar 

  65. Greenhill L, Beyer DH, Finkleson J, et al. Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/ hyperactivity disorder. J Atten Disord. 2002;6(Suppl 1):S89–100.

    PubMed  Google Scholar 

  66. Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(2):171–9.

    Article  PubMed  Google Scholar 

  67. Gadow KD, Arnold LE, Molina BS, et al. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. J Am Acad Child Adolesc Psychiatry. 2014;53(9):948 e1–959 e1.

    Article  PubMed  Google Scholar 

  68. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517–35.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry/MC1410, University of Connecticut Medical School, 263 Farmington Avenue, Farmington, CT, 06030-1410, USA

    Daniel F. Connor

Authors
  1. Daniel F. Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel F. Connor.

Ethics declarations

Conflicts of interest

Dr. Connor reports no conflicts of interest in the preparation of this manuscript.

Funding

No sources of funding were used to assist with the preparation of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Connor, D.F. Pharmacological Management of Pediatric Patients with Comorbid Attention-Deficit Hyperactivity Disorder Oppositional Defiant Disorder. Pediatr Drugs 17, 361–371 (2015). https://doi.org/10.1007/s40272-015-0143-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-015-0143-3

Keywords

Search

Navigation